Loading...
OTCMSHTDY
Market cap8.71bUSD
Dec 24, Last price  
14.20USD
1D
1.94%
1Q
22.10%
Jan 2017
-30.73%
IPO
-35.57%
Name

Sinopharm Group Co Ltd

Chart & Performance

D1W1MN
OTCM:SHTDY chart
P/E
35.70
P/S
0.54
EPS
2.90
Div Yield, %
5.78%
Shrs. gr., 5y
0.96%
Rev. gr., 5y
11.61%
Revenues
596.57b
+8.05%
23,736,642,00031,110,214,00038,187,433,00047,045,853,00069,233,669,000102,224,807,000135,786,836,000166,866,146,000200,131,261,000228,672,929,000258,117,225,000277,028,977,000344,525,821,000425,272,726,000456,414,611,000521,051,235,000552,147,550,000596,569,565,000
Net income
9.05b
-36.89%
182,448,000535,949,000818,103,000845,819,0001,208,751,0001,560,606,0001,973,823,0002,250,002,0002,874,823,0003,760,649,0004,647,344,0007,868,176,0009,404,484,00010,620,072,00012,097,291,00013,064,773,00014,345,442,0009,053,760,000
CFO
17.17b
-18.08%
638,439,000441,180,000653,849,0001,011,505,0001,202,537,0001,019,269,0004,017,209,0004,941,294,0005,560,835,00013,412,333,0009,257,964,0001,667,345,0003,653,739,00018,777,096,00011,154,609,0009,308,085,00020,963,787,00017,173,030,000
Dividend
Jun 18, 20240.601 USD/sh
Earnings
Apr 24, 2025

Profile

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
URL
https://www.sinopharmholding.com/
IPO date
Sep 23, 2009
Employees
113,362
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
596,569,565
8.05%
552,147,550
5.97%
521,051,235
14.16%
Cost of revenue
574,207,650
529,616,610
500,199,153
Unusual Expense (Income)
NOPBT
22,361,915
22,530,940
20,852,082
NOPBT Margin
3.75%
4.08%
4.00%
Operating Taxes
4,502,309
4,218,377
3,938,389
Tax Rate
20.13%
18.72%
18.89%
NOPAT
17,859,606
18,312,563
16,913,693
Net income
9,053,760
-36.89%
14,345,442
9.80%
13,064,773
8.00%
Dividends
(2,558,837)
(2,340,492)
(2,153,253)
Dividend yield
4.01%
3.78%
4.08%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
56,526,974
54,633,193
56,699,696
Long-term debt
22,472,244
19,799,500
16,466,466
Deferred revenue
412,973
376,240
Other long-term liabilities
4,330,584
3,436,277
3,384,255
Net debt
4,639,447
9,370,609
20,452,455
Cash flow
Cash from operating activities
17,173,030
20,963,787
9,308,085
CAPEX
(1,959,570)
(2,417,529)
(2,255,642)
Cash from investing activities
(944,535)
(3,589,622)
(1,266,962)
Cash from financing activities
(7,643,970)
(5,693,481)
(14,693,007)
FCF
8,557,774
16,237,549
1,594,676
Balance
Cash
63,809,085
55,222,122
43,541,177
Long term investments
10,550,686
9,839,962
9,172,530
Excess cash
44,531,293
37,454,706
26,661,145
Stockholders' equity
98,267,244
87,991,373
79,404,355
Invested Capital
153,899,888
142,775,244
142,113,423
ROIC
12.04%
12.86%
12.71%
ROCE
11.27%
12.44%
12.28%
EV
Common stock shares outstanding
3,116,818
3,120,656
3,111,169
Price
20.45
3.07%
19.84
16.98%
16.96
-7.02%
Market cap
63,738,928
2.95%
61,913,815
17.34%
52,765,426
-7.02%
EV
114,114,903
117,675,632
115,373,868
EBITDA
26,792,163
26,695,959
24,774,140
EV/EBITDA
4.26
4.41
4.66
Interest
2,956,587
3,520,326
3,756,835
Interest/NOPBT
13.22%
15.62%
18.02%